Please use this identifier to cite or link to this item: https://hdl.handle.net/1/1490
Title: Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study
Authors: Roger, Simon D ;Spinowitz, B.S.;Fishbane, Steven ;Pergola, P.E.;Lerma, E.V.;Butler, J.;von Haehling, S.;Adler, S.H.;Zhao, J.;Singh, B.;Lavin, P.T.;McCullough, P.A.;Kosiborod, M.;Packham, D.
Affliation: Central Coast Local Health District
Gosford Hospital
Issue Date: Jun-2019
Source: 14(6):798-809
Journal title: Clinical Journal of the American Society of Nephrology
Department: Renal
Abstract: BACKGROUND AND OBJECTIVES: Oral sodium zirconium cyclosilicate (formerly ZS-9) binds and removes potassium via the gastrointestinal tract. Sodium zirconium cyclosilicate-associated restoration and maintenance of normokalemia and adverse events were evaluated in a two-part, open label, phase 3 trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In the correction phase, adult outpatients with plasma potassium >/=5.1 mmol/L (i-STAT Point-of-Care) received sodium zirconium cyclosilicate 10 g three times daily for 24-72 hours until normokalemic (potassium =3.5-5.0 mmol/L). Qualifying participants entered the </=12-month maintenance phase and received sodium zirconium cyclosilicate 5 g once daily titrated to maintain normokalemia without dietary or medication restrictions. Prespecified primary end points were restoration of normal serum potassium values (3.5-5.0 mmol/L) during the correction phase and maintenance of serum potassium </=5.1 mmol/L during the maintenance phase. Adverse events were assessed throughout. RESULTS: Of 751 participants, 746 (99%) achieved normokalemia during the correction phase (mean serum potassium =4.8 mmol/L; 95% confidence interval, 4.7 to 4.8) and entered the maintenance phase; 466 (63%) participants completed the 12-month trial. Participants were predominantly white, men, and age >/=65 years old; 74% had an eGFR<60 ml/min per 1.73 m(2), and 65% used renin-angiotensin-aldosterone system inhibitors. Mean time on sodium zirconium cyclosilicate was 286 days. Mean daily sodium zirconium cyclosilicate dose was 7.2 g (SD=2.6). Over months 3-12, mean serum potassium was 4.7 mmol/L (95% confidence interval, 4.6 to 4.7); mean serum potassium values </=5.1 and </=5.5 mmol/L were achieved by 88% and 99% of participants, respectively. Of 483 renin-angiotensin-aldosterone system inhibitor users at baseline, 87% continued or had their dose increased; 11% discontinued. Among 263 renin-angiotensin-aldosterone system inhibitor-naive participants, 14% initiated renin-angiotensin-aldosterone system inhibitor therapy. Overall, 489 (66%) participants experienced adverse events during the maintenance phase, and 22% experienced a serious adverse event. Of eight (1%) deaths, none were considered related to sodium zirconium cyclosilicate. Nine (1%) and 34 (5%) participants experienced serum potassium <3.0 and 3.0-3.4 mmol/L, respectively. CONCLUSIONS: After achieving normokalemia, individualized once daily sodium zirconium cyclosilicate was associated with maintenance of normokalemia without substantial renin-angiotensin-aldosterone system inhibitor changes for </=12 months.
URI: https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1490
DOI: 10.2215/cjn.12651018
Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/31110051
ISSN: 1555-9041
Publicaton type: Journal Article
Keywords: Kidney Disease
Drug Therapy
Hematology
Haematology
Study or Trial: Clinical Trial
Appears in Collections:Renal Medicine

Show full item record

Page view(s)

16
checked on Feb 2, 2023

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.